AMH and breast carcinoma: Reduced ovarian toxicity observed by combined treatment of trastuzumab and chemotherapy was manifested also in the clinical setting while AMH, a consensus indicator of ovarian reserve, regained to detectable levels post-treatment in a small cohort of breast cancer patients treated with trastuzumab and chemotherapy compared to a small cohort treated with chemotherapy alone.